paclitaxel has been researched along with Adrenal Cortex Cancer in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| da Conceição, BB; da Silva, JCL; de Paula Mariani, BM; Dos Santos Passaia, B; Fragoso, MCBV; Kremer, JL; Lima, K; Lotfi, CFP; Machado-Neto, JA; Zerbini, MCN | 1 |
| Beuschlein, F; Hantel, C; Jung, S; Mussack, T; Reincke, M | 1 |
| Argese, N; Bucci, B; Cerquetti, L; Chimento, A; De Salvo, M; Marchese, R; Pezzi, V; Sampaoli, C; Stigliano, A; Toscano, V; Vottari, S | 1 |
| Bertherat, J; Beuschlein, F; Frantsev, R; Hantel, C; Jäckel, C; Lira, R; Mussack, T; Ozimek, A; Ragazzon, B; Reincke, M | 1 |
| Bussey, KJ; Demeure, MJ; Gately, S; Gonzales, P; Grant, CS; Han, H; Hostetter, G; Kiefer, J; Komorowski, R; Mount, D; Sinari, S; Stephan, E; Von Hoff, DD | 1 |
| Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M | 1 |
| Altavilla, G; Barzon, L; Boscaro, M; Fallo, F; Pagotto, U; Pilon, C; Pistorello, M; Sonino, N | 1 |
| Benis, R; Mattson, P | 2 |
| Kramer, RE; Mason, JI; Rainey, WE; Shay, JW | 1 |
1 trial(s) available for paclitaxel and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
9 other study(ies) available for paclitaxel and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Child, Preschool; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Paclitaxel; Prognosis; RNA, Messenger; Stathmin | 2020 |
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitotane; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
C-MYC modulation induces responsiveness to paclitaxel in adrenocortical cancer cell lines.
Topics: Adrenal Cortex Neoplasms; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Humans; In Situ Nick-End Labeling; Paclitaxel; Proto-Oncogene Proteins c-myc; Transfection | 2015 |
TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; DNA-Binding Proteins; Female; Humans; Interleukin-1 Receptor-Associated Kinases; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Mice, Nude; Nuclear Proteins; Paclitaxel; Proportional Hazards Models; Signal Transduction; Transcriptional Activation; Tumor Necrosis Factor alpha-Induced Protein 3; Tumor Necrosis Factor-alpha; Xanthones; Xenograft Model Antitumor Assays | 2016 |
Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Adenoma; Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Gene Expression Profiling; Humans; Mice; Mitotane; Nanoparticles; Neoplasm Transplantation; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line.
Topics: Adrenal Cortex Neoplasms; Aldosterone; Apoptosis; Cell Survival; Culture Media, Conditioned; Dehydroepiandrosterone Sulfate; DNA Fragmentation; Humans; Hydrocortisone; Paclitaxel; Testosterone; Tumor Cells, Cultured | 1996 |
Microtubules, organelle transport, and steroidogenesis in cultured adrenocortical tumor cells. 1. An ultrastructural analysis of cells in which basal and ACTH-induced steroidogenesis was inhibited by taxol.
Topics: Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Alkaloids; Animals; Male; Mice; Microtubules; Organelles; Paclitaxel; Tumor Cells, Cultured | 1989 |
Microtubules, organelle transport, and steroidogenesis in cultured adrenocortical tumor cells. 2. Reversibility of taxol's inhibition of basal and ACTH-induced steroidogenesis is unaccompanied by reversibility of taxol-induced changes in cell ultrastructu
Topics: Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Alkaloids; Animals; Biological Transport; Mice; Microscopy, Electron; Microtubules; Organelles; Paclitaxel; Time Factors; Tumor Cells, Cultured | 1989 |
The effects of taxol, a microtubule-stabilizing drug, on steroidogenic cells.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Alkaloids; Animals; Bucladesine; Cattle; Cell Line; Cholesterol; Leydig Cells; Male; Mice; Microtubules; Mitochondria; Paclitaxel; Pregnenolone; Progesterone; Steroids; Testicular Neoplasms | 1985 |